| protein
| SFRS10 (target gene for the alternative splicing regulator SFRS10) |
|
Rb binding protein Che-1 (AATF) |
|
apolipoprotein E3 (ApoE3) |
|
calmodulin 1 (phosphorylase kinase, delta) (CALM1) |
|
Fyn kinase (FYN) |
|
prolyl isomerase Pin1 |
|
Presenilin 1 (PSEN1) |
|
S100 calcium binding protein B (S100B) |
|
alpha-synuclein (SNCA) |
|
spectrin (SPTB) |
|
alpha and beta tubulin |
|
ubiquitin |
|
14-3-3zeta protein |
|
beta PP peptide |
|
BCL2-associated athanogene 1 (BAG-1) |
|
Amyloid-beta protein (Abeta) |
|
interacting with CALM1 (the lack of MAPT in neurons changes the subcellular localization of CALM1 and that it correlates with a change in the expression of calbindin)  |
|
SRSF4 binds to the proximal downstream intron of MAPT exon 10 at the FTDP-17 hotspot region and interacts with RBMX and PCBP2 (increased exon 10 inclusion in FTDP mutants may arise from weakened SRSF4 binding)  |
|
GSK3B activity regulates mitochondrial axonal trafficking largely in a MAPT-dependent manner  |
|
MAPT mRNA is a physiological splicing target of FUS  |
|
SRSF6 promoted MAPT exon 10 inclusion, and the promotion of MAPT exon 10 inclusion by SRSF6 required the arginine/serine-rich region, which was responsible for the subnucleic speckle localization  |
|
interaction of endogenous MAPT protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent MAPT phosphorylation  |
|
NUB1 interacted with both MAPT and GSK3B to disrupt their interaction, and abolished recruitment of GSK3B to MAPT inclusions  |
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|  
|  
| --over
|  
| |
in extraskeletal myxoid chondrosarcoma and chordoma | | constitutional
|  
|  
|  
| loss of function
| |
forming tangles of paired helical filaments (PHF) consisting of hyperphosphorylated tau protein in Alzheimer disease | | constitutional
|  
| insertion
|  
|  
| |
inclusion of exon 6c decreases in DM1 (myotonic dystrophy 1) brains compared to control brains whereas inclusion of 6d increases | | constitutional
|  
|  
|  
| gain of function
|
and KLC1 axonal transport defects can initiate neurodegeneration and/or exacerbate human tau-dependent disease pathways in AD and other neurodegenerative tauopathies | | constitutional
|  
|  
| --other
|  
|
splicing misregulation of adult-specific exon 10, which codes for a microtubule binding domain, results in expression of abnormal ratios of tau isoforms, leading to FTDP17  | | constitutional
|  
|  
| --other
|  
|
loss of axonal mitochondria may play an important role in tau phosphorylation and toxicity in the pathogenesis of AD  | |
| Variant & Polymorphism
SNP
, other
| over-representation of the soluble four repeats tau isoforms which may need a genetic defect in tau and a mitochondrial defect either genetic or toxic leading to tau aggregation |
|
SNP H1 preferentially associated with Parkinson disease and H1C with Alzheimer disease |
|
SNP 14 and 21 increasing the risk of progressive supranuclear palsy and corticobasal degeneration |
|
genotypes at SNP9 interact with SNP6 genotypes to increase risk of amyotrophic lateral sclerosis-parkinsonsim/dementia complex of Guam |
|
H1 haplotype increased in neurodegenerative disorders such as progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), frontotemporal dementia (FTD) and Parkinson's disease (PD)  |
|
H2 haplotype has been found to be related to familial FTD |
|
; H1 haplotype is associated with a particular cerebral morphology that may increase the susceptibility of the healthy carriers to develop neurodegenerative diseases such as sporadic tauopathies  |
|
|